ConductScience.org, home

Comparison · NCT00704353-ec79e1f2

Ferric Carboxymaltose (FCM) vs Standard Medical Care: Number of Participants With Treatment-emergent Serious Adverse Events (SAE's)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Ferric Carboxymaltose (FCM) vs Standard Medical Care: Number of Participants With Treatment-emergent Serious Adverse Events (SAE's). Trial comparisons, record NCT00704353-ec79e1f2. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00704353-ec79e1f2

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.01370.005850.0316wilson
Risk in group 20.02440.01290.0457wilson
Risk difference, group 1 minus group 2-0.0107-0.03340.0106newcombe hybrid score
Risk ratio, group 1 over group 20.560.191.66log
Odds ratio, group 1 over group 20.5540.1841.67log
Number needed to treat, for one fewer participant with the outcome on Ferric Carboxymaltose (FCM) than on Standard Medical Care93.2from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Ferric Carboxymaltose (FCM)Subjects received an undiluted dose of iron as FCM (15 mg/kg up to a maximum of 750 mg) at 100 mg/minute on Day 0.5366OG000
Group 2Standard Medical CareReceived standard medical care (as determined by the Investigator) of IDA.9369OG001

Outcome

Type
PRIMARY
Title
Number of Participants With Treatment-emergent Serious Adverse Events (SAE's)
Description
Time frame
through 30 days after the last dose of study drug (FCM or SMC for the treatment of IDA)
Population

Source ClinicalTrials.gov

Trial

Title
Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency Anemia
NCT number
NCT00704353
Phases
PHASE3
Conditions
Anemia
Interventions
Ferric Carboxymaltose, Standard Medical Care (SMC)
Lead sponsor
American Regent, Inc.
Results first posted
2013-11-25

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00704353-ec79e1f2